Literature DB >> 2476356

Immunotherapy using Freund's adjuvant and recombinant interleukin-2 combined with transarterial chemoembolization for hepatocellular carcinoma.

T Ito1, N Ikeda, K Sue, M Ukida, T Higashi, T Okamoto, T Ohsawa, K Nouso, A Watanabe, T Tsuji.   

Abstract

A new immunotherapy for hepatocellular carcinoma (HCC) using Freund's adjuvant and recombinant interleukin-2 (IL-2) combined with conventional transarterial chemoembolization therapy was performed. In 16 patients with HCC and one patient with metastatic liver cancer receiving this therapy, decrease and suppression of reelevation of alpha-fetoprotein after therapy was observed. Disappearance of tumor thrombi of HCC in the main portal vein was observed in a patient, and decrease of carcinoembryonic antigen was also observed in a patient with metastatic liver cancer. The present therapy using Freund's adjuvant and IL-2 is likely to open a new avenue for the treatment of patients with advanced liver cancer.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2476356     DOI： 10.1007/bf02774344

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN： 0435-1339


  8 in total

1.  The mode of action of immunologic adjuvants.

Authors:  J FREUND
Journal:  Bibl Tuberc       Date:  1956

2.  Transcatheter occlusion of abdominal tumors.

Authors:  H M Goldstein; S Wallace; J H Anderson; R L Bree; C Gianturco
Journal:  Radiology       Date:  1976-09       Impact factor: 11.105

3.  Treatment for unresectable hepatoma via selective hepatic arterial infusion of lymphokine-activated killer cells generated from autologous spleen cells.

Authors:  K Okuno; H Takagi; T Nakamura; Y Nakamura; Z Iwasa; M Yasutomi
Journal:  Cancer       Date:  1986-09-01       Impact factor: 6.860

4.  [Clinical features of small hepatocellular carcinomas].

Authors:  T Shinagawa; M Ohto; K Kimura; S Tsunetomi; M Morita; H Saisho; Y Tsuchiya; K Okuda; N Saotome; E Karasawa; M Miki; T Ueno
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  1982-12

5.  Hepatic artery embolization in 120 patients with unresectable hepatoma.

Authors:  R Yamada; M Sato; M Kawabata; H Nakatsuka; K Nakamura; S Takashima
Journal:  Radiology       Date:  1983-08       Impact factor: 11.105

6.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

Authors:  S A Rosenberg; M T Lotze; L M Muul; S Leitman; A E Chang; S E Ettinghausen; Y L Matory; J M Skibber; E Shiloni; J T Vetto
Journal:  N Engl J Med       Date:  1985-12-05       Impact factor: 91.245

7.  Adoptive immunotherapy of cancer: accomplishments and prospects.

Authors:  S A Rosenberg
Journal:  Cancer Treat Rep       Date:  1984-01

8.  Differential diagnosis of hepatic masses on computed tomography, with particular reference to hepatocellular carcinoma.

Authors:  Y Itai; T Araki; S Furui; A Tasaka
Journal:  J Comput Assist Tomogr       Date:  1981-12       Impact factor: 1.826
  8 in total
  2 in total

Review 1.  Immunotherapy and the Interventional Oncologist: Challenges and Opportunities-A Society of Interventional Oncology White Paper.

Authors:  Joseph P Erinjeri; Gabriel C Fine; Gosse J Adema; Muneeb Ahmed; Julius Chapiro; Martijn den Brok; Rafael Duran; Stephen J Hunt; D Thor Johnson; Jens Ricke; Daniel Y Sze; Beau Bosko Toskich; Bradford J Wood; David Woodrum; S Nahum Goldberg
Journal:  Radiology       Date:  2019-04-23       Impact factor: 11.105

Review 2.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.